Today we’re observing Rare Disease Day® 2019. We’re joining more than 100 organizations world-wide in the worthy cause of raising awareness about the challenges that rare disease patients and their families face every day of the year.
At Variantyx we’re passionate about providing comprehensive, cost-effective genomic testing to patients using whole genome sequencing (WGS) – a technology that provides better insights into the molecular cause behind patients’ clinical symptoms, oftentimes ending years’ long diagnostic odysseys.
Which is why we’re so excited to announce the launch of our RareDx program. This program is our philanthropic effort to help end the diagnostic odyssey for underserved, undiagnosed rare disease patients. For selected patients, we will provide our Variantyx Unity™ test at no cost. We are committed to providing testing through the program for a minimum of 12 patients each year.
Beginning today, February 28, 2019, we are accepting clinician-sponsored applications for pediatric or adolescent patients whose clinical symptoms are believed to have a genetic etiology and whose families do not have the financial means to pay for the testing.
More information about the RareDx program, including a downloadable application, is available on our RareDx program page.